Indices of lipid panel in patients with essential hypertension, complicated with hemorrhagic stroke, after an early recovery period
DOI:
https://doi.org/10.32402/dovkil2019.01.010Keywords:
hemorrhagic stroke, essential hypertension, lipid panel, atherosclerosis, statinsAbstract
Objective: to determine lipid panel indices in patients with essential hypertension (EH), complicated with hemorrhagic stroke (HS), after an early recovery period; to establish a formula for calculating the dose of rosuvastatin for such patients and to assess the safety profile of its treatment in 3 months after the starting date of 1-month treatment period. Materials and methods. There were formed 2 groups of people: 107 persons (56 women and 51 men, average (M±σ) age – 54,0±9,5 years) were involved in the main group, who have undergone HS as a complication of EH 6 months and more previously; the comparison group comprised 104 persons (54 women and 50 men, middle age 53,7±8,9 years old) with EH. They were matched groups according to key indicators. All the above-mentioned people underwent blood analysis on lipid panel indices. Results. Lipid panel indices in the main and control group (M±σ) were the following ones, respectively: total cholesterol 5,998±1,326 vs. 6,027±1,103 mmol/l; triglycerides 1,422±0,775 vs. 1,975±1,136 mmol/l; low density lipoprotein 4,196±1,021 vs. 4,301±0,884 mmol/l; very low density lipoprotein 0,619±0,356 vs. 0,719±0,268 mmol/l; high density lipoprotein 1,418±0,301 vs. 1,318±0,252 mmol/l, the difference is significant (p<0,05); the atherogenicity coefficient of 3,438±1,008 vs. 3,616±0,898. Conclusions. Patients with EH, who have suffered HS more than 6 months before and have recovered up to 50-100 points according to Barthel scale, compared with patients with EH stage II, have similar mean values of lipid panel indices, with the exception of high density lipoprotein index, which is bigger in patients with former cerebrovascular injury. A formula for selecting dosage of rosuvastatin has been developed to obtain the resulting low density lipoprotein level in the range of 2,198-2,500 mmol/l for the treatment after 6 months period from the incidence case of HS. It was determined that in the next 3 months period in case of rosuvastatin treatment of persons with former HS during the one-month period, there are no adverse effects in the form of further complications of HS.Downloads
References
1. Гусев Е. И., Скворцова В. И., Чекнева Н. С. и др. Лечение острого мозгового инсульта (диагностические и терапевтические алгоритмы) : учебно-методическая литература. М., 1997.
2. Литовский И.А., Гордиенко А.В. Атеросклероз и гипертоническая болезнь: вопросы патогенеза, диагностики и лечения. СПб. : СпецЛит, 2013. 304 с.
3. Профілактика серцево-судинних захворювань. Адаптована клінічна настанова, заснована на доказах / Державний експертний центр МОЗ України ; Асоціація кардіологів України. 2016. 127 с. URL : http://www.volyncard.in.ua/files/protocols/2016_564_AKN_PSSZ.pdf
4. Ткачишин О.В. Ультразвукова оцінка гемодинаміки та морфології магістральних артерій шиї у хворих на гіпертонічну хворобу, асоційовану з геморагічним інсультом. Український нейрохірургічний журнал. 2018. № 2. С. 69-78.
5. Уніфікований клінічний протокол екстреної, первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги та медичної реабілітації «Геморагічний інсульт (внутрішньомозкова гематома, аневризмальний субарахноїдальний крововилив)» : Наказ МОЗ України від 17.04.2014 № 275. URL : http://mtd.dec.gov.ua/images/dodatki/2014_275_GI/2014_275_YKPMD_GI.pdf
6. Adams S.P., Sekhon S.S., Wright J.M. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev. 2014. №11. CD010254. https://doi.org/10.1002/14651858.CD010254.pub2
7. Asberg S., Eriksson M. Statin therapy and the risk of intracerebral haemorrhage: a nationwide observational study. Int. J. Stroke. 2015. № 10. P. 46–49. https://doi.org/10.1111/ijs.12539
8. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016. Vol. 253. P. 281-344. https://doi.org/10.1016/j.atherosclerosis.2016.08.018
9. Chen J.H., Wu T., Yang L.K., Chen L., Zhu J., Li P.P., Hu X., Wang Y.H. Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage. Mol Med Rep. 2018. Vol. 17(1). P. 1651-1659. https://doi.org/10.3892/mmr.2017.8074
10. Chen Yu-Wei, Li Chen-Hua, Yang Chih-Dong, Liu Chung-Hsiang, Chen Chih-Hung, Sheu Jau-Jiuan et al. Taiwan Stroke Registry Investigators. Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. PLoS One. 2017. Vol. 12(4). e0171379. doi: 10.1371/journal.pone.0171379. https://doi.org/10.1371/journal.pone.0171379
11. Endres M., Nolte C.H., Scheitz J.F. Statin Treatment in Patients With Intracerebral Hemorrhage. Stroke. 2018. Vol. 49(1). P. 240-246. https://doi.org/10.1161/STROKEAHA.117.019322
12. Ferket B.S., van Kempen B.J., Wieberdink R.G., Steyerberg E.W., Koudstaal P.J., Hofman A., Shahar E. et al. Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology. 2014. Vol. 82 (20). P. 1804-1812. https://doi.org/10.1212/WNL.0000000000000427
13. Hemphill JC 3rd, Greenberg S.M., Anderson C.S., Becker K., Bendok B.R., Cushman M. et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015. Vol. 46 (7). P. 2032-2060. https://doi.org/10.1161/STR.0000000000000069
14. Hongo M., Kumazaki S., Izawa A., Hidaka H., Tomita T., Yazaki Y., Kinoshita O., Ikeda U. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ J. 2011. Vol. 75(11). P. 2660-2667. https://doi.org/10.1253/circj.CJ-11-0497
15. Jellinger P.S., Handelsman Y., Rosenblit P.D., Bloomgarden Z.T., Fonseca V.A., Garber A.J. et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017. Vol. 23(Suppl 2). P. 1-87. https://doi.org/10.4158/EP171764.APPGL
16. Kirkpatrick P.J., Turner C.L., Smith C., Hutchinson P.J., Murray G.D. STASH Collaborators Simvastatin in aneurismal subarachnoid haemorrhage (STASH): a multicentre randomized phase 3 trial. Lancet Neurol. 2014. Vol. 13(7). P. 666-675. https://doi.org/10.1016/S1474-4422(14)70084-5
17. Kotlęga D., Masztalewicz M., Ciećwież S., Nowacki P. Potential role of statins in the intracerebral hemorrhage and subarachnoid hemorrhage. Neurol Neurochir Pol. 2015. Vol. 49(5). P. 322-328. https://doi.org/10.1016/j.pjnns.2015.07.007
18. Ouweneel A.B., Van Eck M. Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation. Vascul Pharmacol. 2016. Vol. 82. P.1-10. https://doi.org/10.1016/j.vph.2015.10.009
19. Pandit A.K., Kumar P., Kumar A., Chakravarty K., Misra S., Prasad K. High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand. 2016. Vol. 134(1). P. 22-28. https://doi.org/10.1016/j.vph.2015.10.009
20. Tai S.Y., Lin F.C., Lee C.Y., Chang C.J., Wu M.T., Chien C.Y. Statin use after intracerebral hemorrhage: a 10-year nationwide cohort study. Brain Behav. 2016. Vol. 6(8). e00487. https://doi.org/10.1002/brb3.487
21. Tapia-Perez H., Sanchez-Aguilar M., Torres-Corzo J.G., Rodriguez-Leyva I., Gonzalez-Aguirre D., Gordillo-Moscoso A., Chalita-Williams C. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cent Eur Neurosurg. 2009. Vol. 70(1). P.15-20. https://doi.org/10.1055/s-0028-1082064
22. Uekawa K., Hasegawa Y., Ma M., Nakagawa T., Katayama T., Sueta D., Toyama K., Kataoka K. et al. Rosuvastatin ameliorates early brain injury after subarachnoid hemorrhage via suppression of superoxide formation and nuclear factor-kappa B activation in rats. J Stroke Cerebrovasc Dis. 2014. Vol. 23(6). P.1429-1439. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.12.004
23. Van Matre E.T., Sherman D.S., Kiser T.H. Management of intracerebral hemorrhage – use of statins. Vasc Health Risk Manag. 2016. Vol. 12. P. 153-161. https://doi.org/10.2147/VHRM.S75399
24. Versmissen J., Scheele M., Dippel D.W., van den Meiracker A.H. [Statins after intracerebral haemorrhage: is this safe?]. Ned Tijdschr Geneeskd. 2015. Vol. 159. A8563.
25. Vuorio A., Kaste M., Kovanen P.T. Combination of intracerebral haemorrhage and familial hypercholesterolemia in the acute hospital setting – a challenge for statin treatment? Int J Stroke. 2015. Vol. 10 (4). P. 467-8. https://doi.org/10.1111/ijs.12492
26. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018. Vol. 39. P. 3021–3104. https://doi.org/10.1093/eurheartj/ehy339
27. Wood W.G., Eckert G.P., Igbavboa U., Muller W.E. Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci. 2010. 1199. P. 69–76. https://doi.org/10.1111/j.1749-6632.2009.05359.x
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Environment & Health
This work is licensed under a Creative Commons Attribution 4.0 International License.
